Neupharm Sp. z o.o. I Wspolnicy sp. k. Company Profile - Poland | Financials & Key Executives

Neupharm Sp. z o.o. I Wspolnicy sp. k. (Poland)

Main Activities: All Other Professional, Scientific, and Technical Services

Secondary Activities: Pharmaceutical Preparation Manufacturing | Chemical and Allied Products Merchant Wholesalers | Other Miscellaneous Nondurable Goods Merchant Wholesalers | Wholesale Trade Agents and Brokers | Pharmacies and Drug Stores | Department Stores | Administrative Management and General Management Consulting Services | Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

Full name: Neupharm Sp. z o.o. I Wspolnicy sp. k.

Profile Updated: March 20, 2025

Neupharm Sp. z o.o. I Wspolnicy sp. k. is based in Poland, with the head office in Mszczonow. It operates in the All Other Professional, Scientific, and Technical Services sector. It was first established on December 18, 2017. The latest financial highlights indicate a net sales revenue increase of 315.38% in 2023. Its’ total assets recorded a growth of 519.73%. The net profit margin of Neupharm Sp. z o.o. I Wspolnicy sp. k. decreased by 45.87% in 2023.

Headquarters
Ul. Lugowa 85
Mszczonow; Mazowieckie; Postal Code: 96-320

Contact Details: Purchase the Neupharm Sp. z o.o. I Wspolnicy sp. k. report to view the information.

Basic Information

Financial Auditors:

Purchase the Neupharm Sp. z o.o. I Wspolnicy sp. k. report to view the information.

Incorporation Date:

December 18, 2017

Company Performance

Financial values in the chart are available after Neupharm Sp. z o.o. I Wspolnicy sp. k. report is purchased.

Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service

Key Financial Highlights

Annual growth percentages for latest two years in local currency PLN. Absolute financial data is included in the purchased report.

Net sales revenue

315.38%▲

Total operating revenue

317.79%▲

Operating profit (EBIT)

-7.8%▼

EBITDA

-7.8%▼

Net Profit (Loss) for the Period

-20.42%▼

Total assets

519.73%▲

Total equity

N/A

Operating Profit Margin (ROS)

-44.15%▼

Net Profit Margin

-45.87%▼

Return on Equity (ROE)

N/A

Similar companies